- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02933177
Effectiveness of Flash Mediation Therapy
Study on Effectiveness of Flash Mediation Therapy in the Context of Acute Psychological and Behavioral Symptoms of Dementia in Nursing Homes
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France
- Hôpital des Charpennes Centre de Recherche Clinique "Vieillissement-Cerveau-Fragilité"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- People ability to object and does not oppose either by themselves or through a trusted person referred to in Article L. 1111-6 of the Code of Public Health, failing thereof, by the family, or, if a person talking to the person close and stable ties. For adults under guardianship, permission must be given by the legal representative of the person. The research will benefit from the backing of Persons Protection Committee (PPC) prior to its implementation;
- Man or woman over 60 years;
- patient living in one of the nursing homes participating in the project;
- Patient completing the diagnostic criteria for major neurocognitive disorder according to Diagnostic and Statistical Manual of Mental Disorders V criteria (DSM-V)
- The patient must have at least one of these productive symptoms (agitation, aberrant motor behavior, disinhibition) listed by the NPI-NH (score> 2 at least one of these items)
Exclusion Criteria:
- Deafness or blindness may compromise patient assessment or participation in the intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2 months control condition - 4 months chariot-flash
200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention).
The experimental condition is to propose the "chariot-flash" in emergency during the emergence or increase of productive symptoms.
|
The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms. The "chariot-flash" condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):
|
Experimental: 4 months control condition-2 months chariot flash
200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
|
The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms. The "chariot-flash" condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in number of disorders
Time Frame: until 4 months
|
the number of disorders are evaluated with Cohen Mansfield Agitation Inventory (CMAI) before and 30 minutes after each intervention. The original version of the CMAI is initially planned to study the frequency of these disorders. However, the goal being to study the decrease in productive symptoms, after using the "chariot-flash", only the number of this item will be considered (between 0 and 29). For example in this modified version, for the item "pace, aimless wandering" nursing team can answer "present" or "absent" instead of (never, less than once a week, once or twice per week, a few times over week, one to two times daily, several times a day, several times per hour) |
until 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in score of well-being
Time Frame: until 4 months
|
the score of well-being is assessed using the Instant Well-Being scale (Evaluation Instantané du Bien-Etre : EVIBE) before and 30 minutes after each intervention . The EVIBE is a visual analogue scale for reporting the status of well-being of the patient at a specific time. On a graduated scale from 0 to 5, the caregiver should position a cursor position to the left corresponding to the feeling of well-being the lowest and the right position to the feeling of well-being the highest. |
until 4 months
|
change in psychotropic drugs prescribed
Time Frame: until 4 months
|
The caregiver or doctor will check on a board what are the treatments that have been added or modified (compared to the usual treatment) in response to behavioral disorder
|
until 4 months
|
change in score of BPSD
Time Frame: before the beginning of the study, at 2 months, 4 months and 6 months
|
the score of BPSD is assessed using the neuropsychiatric inventory nursing home version (NPI-NH). Each of the 12 BPSD (delusions, hallucinations, agitation, depression, anxiety, excitement, apathy, disinhibition, depression, motor aberrant behavior, sleep and appetite) is evaluated on 12 depending on its frequency and severity (global score =144). |
before the beginning of the study, at 2 months, 4 months and 6 months
|
change in level of agitation
Time Frame: before the beginning of the study, at 2 months, 4 months and 6 months
|
the level of agitation is assessed using the original version of CMAI.
The CMAI lists 29 agitation and aggressive behaviors by frequency (0: not evaluable 1: never, 2: less than once a week 3 : once or twice per week, 4 : a few times over week, 5: one to two times daily, 6 : several times a day, 7 : several times per hour) to obtain a score ranging from 0-203.
|
before the beginning of the study, at 2 months, 4 months and 6 months
|
change in the number of administered psychotropic drugs.
Time Frame: before the beginning of the study, at 2 months, 4 months and 6 months
|
The caregiver or doctor will check on a board on which is written all psychotropic treatments that the patient takes and the dosage
|
before the beginning of the study, at 2 months, 4 months and 6 months
|
The number of hospitalization
Time Frame: at 2 months, 4 months and 6 months
|
The caregiver or doctor will refer in a table the different hospitalizations during the study and their date
|
at 2 months, 4 months and 6 months
|
The number of fall
Time Frame: at 2 months, 4 months and 6 months
|
The caregiver or doctor will refer in a table the different falls during the study and their date.
|
at 2 months, 4 months and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierre Krolak Salmon, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL16_0442
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on 2 months control condition - 4 months chariot-flash
-
Beth Israel Medical CenterCompleted
-
Amsterdam UMC, location VUmcNetherlands Brain Foundation; GGZ inGeest; International Parkinson Foundation... and other collaboratorsCompletedDepression | Parkinson's DiseaseNetherlands
-
University of BelgradeCompleted
-
GlaxoSmithKlineNo longer availablePrimary Myelofibrosis | Myelofibrosis
-
Institut Paoli-CalmettesRecruiting
-
University of Arkansas, FayettevilleRecruiting
-
DuPont Nutrition and HealthCompletedMuscle SynthesisUnited States
-
Sinovac Biotech Co., LtdCompleted
-
Imperial College LondonEngineering and Physical Sciences Research Council, UKNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterRockefeller UniversityRecruitingLiver CancerUnited States